Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 50, Issue 1, 2019, Pages 5-23

  Ma, Christopher ^a,b   Lee, Jeffrey K ^c,d   Mitra, Anish R ^e   Teriaky, Anouar ^f   Choudhary, Daksh ^a   Nguyen, Tran M ^b   Vande Casteele, Niels ^g   Khanna, Reena ^f   Panaccione, Remo ^a   Feagan, Brian G ^b,f   Jairath, Vipul ^b,f  

^a UNIVERSITY OF CALGARY   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c DIVISION OF RESEARCH   (United States)

^d KAISER PERMANENTE   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FILGOTINIB; JANUS KINASE INHIBITOR; JNJ 54781532; PEFICITINIB; PLACEBO; TD 1473; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UPADACITINIB; ANTIINFLAMMATORY AGENT;

BREAST CANCER; CROHN DISEASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HEALING; HERPES ZOSTER; HUMAN; INFECTION; INFLAMMATORY BOWEL DISEASE; INTESTINE ENDOSCOPY; MALIGNANT NEOPLASM; MELANOMA; META ANALYSIS (TOPIC); OPEN STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SKIN CANCER; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; META ANALYSIS;

ANTI-INFLAMMATORY AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; JANUS KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 85066890508     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.15297     Document Type: Review

References (56)

1. Duijvestein M, Battat R, Vande Casteele N, et al. Novel therapies and treatment strategies for patients with inflammatory bowel disease. Curr Treat Options Gastroenterol. 2018;16:129-146.
2. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106:685-698.
3. Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut. 2017;66:199-209.
4. van der Valk ME, Mangen MJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut. 2014;63:72-79.
5. Bonovas S, Fiorino G, Allocca M, et al. Therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016;14:1385-1397 e1310.
6. D'Amico F, Fiorino G, Furfaro F, Allocca M, Danese S. Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. Expert Opin Investig Drugs. 2018;27:595-599.
7. O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368:161-170.
8. Kiu H, Nicholson SE. Biology and significance of the JAK/STAT signalling pathways. Growth Factors. 2012;30:88-106.
9. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008;40:955-962.
10. Rossin EJ, Lage K, Raychaudhuri S, et al. Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genet. 2011;7:e1001273.
11. Galien R. Janus kinases in inflammatory bowel disease: Four kinases for multiple purposes. Pharmacol Rep. 2016;68:789-796.
12. Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT Signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77:521-546.
13. Olivera P, Danese S, Peyrin-Biroulet L. JAK inhibition in inflammatory bowel disease. Expert Rev Clin Immunol. 2017;13:693-703.
14. Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47:454-465.
15. Paschos P, Katsoula A, Salanti G, Giouleme O, Athanasiadou E, Tsapas A. Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life. Aliment Pharmacol Ther. 2018;48:1174-1185.
16. Panés J, Sandborn WJ, Schreiber S, et al. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017;66:1049-1059.
17. Sandborn WJ, Ghosh S, Panes J, et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014;12:1485-1493 e1482.
18. Sands BE, Sandborn WJ, Feagan BG, et al. Peficitinib, an oral janus kinase inhibitor, in moderate-to-severe ulcerative colitis: results from a randomised, phase 2 study. J Crohns Colitis. 2018;12:1158-1169.
19. Winthrop KL, Curtis JR, Lindsey S, et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol. 2017;69:1960-1968.
20. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
21. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
22. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004;60:505-512.
23. Schroeder KW, Tremaine WJ, Ilstrup DM. Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.
24. Ma C, Hussein IM, Al-Abbar YJ, et al. Heterogeneity in definitions of efficacy and safety endpoints for clinical trials of Crohn's disease: A systematic review. Clin Gastroenterol Hepatol. 2018;16:1407–1419 e1422.
25. Ma C, Panaccione R, Fedorak RN, et al. Heterogeneity in definitions of endpoints for clinical trials of ulcerative colitis: a systematic review for development of a core outcome set. Clin Gastroenterol Hepatol. 2018;16: 637–647 e613.
26. Higgins J, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
27. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.
28. Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389:266–275.
29. Sandborn WJ, Feagan BG, Panes J, et al. Safety and efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as induction therapy in patients with crohn's disease: results from celest. Gastroenterology. 2017;152:S1308–S1309.
30. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367:616–624.
31. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–1736.
32. Sandborn WJ, Ghosh S, Panes J, et al. Efficacy and safety of upadacitinib as an induction therapy for patients with moderately-to-severely active ulcerative colitis: data from the phase 2b study U-ACHIEVE. United European Gastroenterol J. 2018;6:A74.
33. Sandborn WJ, Bhandari R, Leighton J, et al. The intestinally restricted, orally administered, PAN-JAK inhibitor TD-1473 demonstrates favorable safety, tolerability, pharmacokinetics and signal for clinical activity in subjects with moderately-to-severely active ulcerative colitis. United European Gastroenterol J. 2018;6(Suppl. 1).
34. Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7:e135.
35. Vasudevan A, Gibson PR, vanLangenberg DR. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? World J Gastroenterol. 2017;23:6385–6402.
36. Panes J, Sandborn WJ, Loftus EV, et al. Efficacy and safety of upadacitinib maintenance treatment for moderate to severe Crohn's disease: Results from the Celest study. Gastroenterology. 2018;154:S-178-S-179.
37. Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47:162–175.
38. Jairath V, Jeyarajah J, Zou G, et al. A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score. Lancet Gastroenterol Hepatol. 2019;4:63–70.
39. Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57:5023–5038.
40. Yamaoka K, Saharinen P, Pesu M, Holt VE 3rd, Silvennoinen O, O'Shea JJ. The Janus kinases (Jaks). Genome Biol. 2004;5:253.
41. Sandborn WJ, Panés J, D’Haens GR, et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials. Clin Gastroenterol Hepatol 2018. [Epub ahead of print]. https://doi.org/10.1016/j.cgh.2018.11.035
42. Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76:1253–1262.
43. Colombel JF. Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention. Inflamm Bowel Dis. 2018;24:2173–2182.
44. Winthrop KL, Melmed GY, Vermeire S, et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2018;24:2258–2265.
45. Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:420–429.
46. Ku CC, Zerboni L, Ito H, Graham BS, Wallace M, Arvin AM. Varicella-zoster virus transfer to skin by T Cells and modulation of viral replication by epidermal cell interferon-alpha. J Exp Med. 2004;200:917–925.
47. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–2096.
48. Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019–1032.
49. Choy EH. Clinical significance of Janus kinase inhibitor selectivity. Rheumatology (Oxford). 2018. [Epub ahead of print]. https://doi.org/10.1093/rheumatology/kez339
50. Can G, Tezel A, Gürkan H, et al. Tyrosine kinase-2 gene polymorphisms are associated with ulcerative colitis and Crohn's disease in Turkish Population. Clin Res Hepatol Gastroenterol. 2015;39:489–498.
51. Sato K, Shiota M, Fukuda S, et al. Strong evidence of a combination polymorphism of the tyrosine kinase 2 gene and the signal transducer and activator of transcription 3 gene as a DNA-based biomarker for susceptibility to Crohn's disease in the Japanese population. J Clin Immunol. 2009;29:815–825.
52. De Vries L, Wildenberg ME, De Jonge WJ, D'Haens GR. The future of janus kinase inhibitors in inflammatory bowel disease. J Crohns Colitis. 2017;11(7):885–893.
53. Xie JH, gillooly K, zhang Y, et al. 349 - BMS-986165 is a highly potent and selective allosteric inhibitor of TYK2, blocks Il-12, IL-23 and type I interferon signaling and provides for robust efficacy in preclinical models of inflammatory bowel disease. Gastroenterology. 2018;154:S-1357.
54. Shah H, Bilodeau M, Burak KW, et al. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. CMAJ. 2018;190:E677–E687.
55. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18:191–198.
56. Higgins PD, Rubin DT, Kaulback K, Schoenfield PS, Kane SV. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther. 2009;29:247–257.